$1.2688
-0.0212[-1.64%]
At close: Apr 16
$1.2688
0[0.00%]
PreMarket: 4:03PM EDT
Biodesix
(NASDAQ:BDSX)Biodesix Stock (NASDAQ:BDSX), Analyst Ratings, Price Targets, Predictions
Biodesix Inc has a consensus price target of $7.88, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, Canaccord Genuity, and Morgan Stanley on March 4, 2024, December 7, 2023, and May 12, 2022. With an average price target of $4 between Canaccord Genuity, Canaccord Genuity, and Morgan Stanley, there's an implied 215.26% upside for Biodesix Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Morgan Stanley
Cowen & Co.
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Biodesix
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/04/2024 | BDSX | Buy Now | Biodesix | $1.27 | 175.85% | Canaccord Genuity | Kyle Mikson | → $3.5 | Reiterates | Buy → Buy | Get Alert |
| 12/07/2023 | BDSX | Buy Now | Biodesix | $1.27 | 175.85% | Canaccord Genuity | Kyle Mikson | → $3.5 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2022 | BDSX | Buy Now | Biodesix | $1.27 | 294.07% | Morgan Stanley | Tejas Savant | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 04/20/2022 | BDSX | Buy Now | Biodesix | $1.27 | — | Cowen & Co. | Max Masucci | — | Initiates | → Outperform | Get Alert |
| 11/17/2021 | BDSX | Buy Now | Biodesix | $1.27 | 766.96% | Morgan Stanley | Tejas Savant | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 05/12/2021 | BDSX | Buy Now | Biodesix | $1.27 | 1712.74% | Morgan Stanley | — | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Biodesix (BDSX)?
The latest price target for Biodesix (NASDAQ: BDSX) was reported by Canaccord Genuity on March 4, 2024. The analyst firm set a price target for $3.50 expecting BDSX to rise to within 12 months (a possible 175.85% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biodesix (BDSX)?
The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Canaccord Genuity, and Biodesix reiterated their buy rating.
When was the last upgrade for Biodesix (BDSX)?
There is no last upgrade for Biodesix.
When was the last downgrade for Biodesix (BDSX)?
The last downgrade for Biodesix Inc happened on November 17, 2021 when Morgan Stanley changed their price target from $21 to $11 for Biodesix Inc.
When is the next analyst rating going to be posted or updated for Biodesix (BDSX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on March 4, 2024 so you should expect the next rating to be made available sometime around March 4, 2025.
Is the Analyst Rating Biodesix (BDSX) correct?
While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a reiterated with a price target of $0.00 to $3.50. The current price Biodesix (BDSX) is trading at is $1.27, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.